Table 1 Interview participant characteristics
Characteristic | Total sample (NÂ =Â 20) |
|---|---|
Age (years), mean (SD), range | 50 (11), 24–68 |
Gender, n (%) | Â |
Female | 15 (75) |
Male | 5 (25) |
Race/ethnicity,* n (%) | Â |
White | 15 (75) |
African American or Black | 3 (15) |
Asian | 1 (5) |
Hispanic, Latin American, or Latinx | 1 (5) |
Education, n (%) | Â |
Less than high school | 1 (5) |
High school diploma or equivalent (e.g., GED) | 4 (20) |
Technical school or associate’s degree | 3 (15) |
Some college | 4 (20) |
College degree (bachelor’s degree) | 6 (30) |
Professional or advanced degree | 2 (10) |
Employment status, n (%) | Â |
Full time | 6 (30) |
Part time | 3 (15) |
Self employed | 2 (10) |
Unemployed and not looking for work | 5 (25) |
Retired | 4 (20) |
Currently taking selexipag, n (%) | Â |
Yes | 15 (75) |
No longer taking | 5 (25) |
WHO Functional Class, †n (%) |  |
I | 2 (10) |
II | 10 (50) |
III | 7 (35) |
IV | 1 (5) |
Severity of current PAH symptoms (self-report), n (%) | Â |
Mild | 6 (30) |
Moderate | 12 (60) |
Severe | 2 (10) |
PAH diagnosis year, mean (SD), range | 2015 (4.6), 2004–2021 |
Current PAH treatment regimen, n (%) | Â |
Selexipag monotherapy | 0 |
Selexipag and a medication targeting one other pathway (double therapy) | 3 (15) |
Selexipag and medications targeting two other pathways (triple therapy) | 12 (60) |
Not currently taking selexipag | 5 (25) |
Current PAH medication(s),*‡ n (%) |  |
Nitric oxide pathway | Â |
 Tadalafil | 8 (40) |
 Sildenafil | 7 (35) |
 Riociguat | 5 (25) |
Endothelin receptor antagonists | Â |
 Macitentan | 10 (50) |
 Ambrisentan | 5 (25) |
 Bosentan | 1 (5) |
Drugs acting on the prostacyclin pathway | Â |
 Selexipag | 15 (75) |
 Treprostinil (intravenous or subcutaneous) | 3 (15) |
 Treprostinil (inhaled) | 2 (10) |